Search

Displaying results 5361 - 5370 of 10000 in total
  1. Drug

    ALT-2074

    go.drugbank.com/drugs/DB05631
    Investigational

    An organoselenium drug previously studied by Oxis International in Phase-II clinical trials for ulcerative colitis patients. Some indications of efficacy were demonstrated. … BXT-51072 has enthusiastic endorsement for treatment in cardiovascular indications, primarily because of its ability to mimic the function of glutathione peroxidase.

  2. Drug

    NV1020

    go.drugbank.com/drugs/DB04969
    Investigational

    NV1020, a genetically engineered herpes simplex virus, is a novel anticancer therapeutic.

  3. Drug

    Vinpocetine

    go.drugbank.com/drugs/DB12131
    Investigational

    Vinpocetine has been investigated for the treatment of Epilepsy.

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    Apatorsen

    go.drugbank.com/drugs/DB06094
    Investigational

    Apatorsen is a second generation antisense drug which in preclinical experiments, inhibits production of Heat Shock Protein 27 (Hsp27) a cell survival protein found at elevated levels in many human cancers

  5. Drug

    Strontium malonate

    go.drugbank.com/drugs/DB05732
    Investigational

    Strontium malonate is being developed as a novel orally available pharmaceutical for the treatment and prevention of osteoporosis. It is being developed by Osteologix Inc.

  6. Drug

    Xamoterol

    go.drugbank.com/drugs/DB13781
    Approved

    Xamoterol is a β1-adrenoceptor partial agonist that has shown to improve systolic and diastolic function in studies with heart failure patients. … It modulates the sympathetic control of the heart but has no agonist action on β2-adrenoceptors.

  7. Drug

    CYC116

    go.drugbank.com/drugs/DB05198
    Investigational

    In preclinical studies, CYC116 has demonstrated antitumor activity in both solid tumors and hematological cancers. … CYC116 is a novel anticancer compound with a unique target profile involving both cell cycle and angiogenesis inhibition mechanisms.

  8. Drug

    Brasofensine

    go.drugbank.com/drugs/DB04857
    Experimental

    In November 2001, NeuroSearch confirmed that the drug's development was discontinued in favor of NS 2230. … Brasofensine is an orally administered dopamine reuptake inhibitor being developed for the treatment of Parkinson's Disease. Phase I/II trials for brasofensine have been completed in the U.K.

  9. Drug

    Octamoxin

    go.drugbank.com/drugs/DB09249
    ApprovedWithdrawn

    This drug was used in the past as an antidepressant agent in the 1960s, however, has since been discontinued. … Octamoxin, also known as _2-octylhydrazine_, is both an irreversible and nonselective monoamine oxidase enzyme inhibitor (MAOI) of the _hydrazine_ chemical class.

  10. Drug

    Tetrahydrofolic acid

    go.drugbank.com/drugs/DB00116
    InvestigationalNutraceutical

    It is converted into 5,10-methylenetetrahydrofolate by serine hydroxymethyltransferase. It is a soluble coenzyme in many reactions, especially in the metabolism of amino acids and nucleic acids. … Tetrahydrofolic acid is a folic acid derivative that is produced from dihydrofolic acid after conversion by dihydrofolate reductase.